<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250104071827&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250104071827&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 04 Jan 2025 12:18:30 +0000</lastbuilddate>
<pubDate>Fri, 03 Jan 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Molecular basis of proton sensing by G protein-coupled receptors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39753132/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250104071827&amp;v=2.18.0.post9+e462414
      <description>Three proton-sensing G protein-coupled receptors (GPCRs)-GPR4, GPR65, and GPR68-respond to extracellular pH to regulate diverse physiology. How protons activate these receptors is poorly understood. We determined cryogenic-electron microscopy (cryo-EM) structures of each receptor to understand the spatial arrangement of proton-sensing residues. Using deep mutational scanning (DMS), we determined the functional importance of every residue in GPR68 activation by generating ∼9,500 mutants and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 26:S0092-8674(24)01373-4. doi: 10.1016/j.cell.2024.11.036. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Three proton-sensing G protein-coupled receptors (GPCRs)-GPR4, GPR65, and GPR68-respond to extracellular pH to regulate diverse physiology. How protons activate these receptors is poorly understood. We determined cryogenic-electron microscopy (cryo-EM) structures of each receptor to understand the spatial arrangement of proton-sensing residues. Using deep mutational scanning (DMS), we determined the functional importance of every residue in GPR68 activation by generating ∼9,500 mutants and measuring their effects on signaling and surface expression. Constant-pH molecular dynamics simulations provided insights into the conformational landscape and protonation patterns of key residues. This unbiased approach revealed that, unlike other proton-sensitive channels and receptors, no single site is critical for proton recognition. Instead, a network of titratable residues extends from the extracellular surface to the transmembrane region, converging on canonical motifs to activate proton-sensing GPCRs. Our approach integrating structure, simulations, and unbiased functional interrogation provides a framework for understanding GPCR signaling complexity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39753132/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">39753132</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.036>10.1016/j.cell.2024.11.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39753132</guid>
<pubDate>Fri, 03 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Matthew K Howard</dc:creator>
<dc:creator>Nicholas Hoppe</dc:creator>
<dc:creator>Xi-Ping Huang</dc:creator>
<dc:creator>Darko Mitrovic</dc:creator>
<dc:creator>Christian B Billesbølle</dc:creator>
<dc:creator>Christian B Macdonald</dc:creator>
<dc:creator>Eshan Mehrotra</dc:creator>
<dc:creator>Patrick Rockefeller Grimes</dc:creator>
<dc:creator>Donovan D Trinidad</dc:creator>
<dc:creator>Lucie Delemotte</dc:creator>
<dc:creator>Justin G English</dc:creator>
<dc:creator>Willow Coyote-Maestas</dc:creator>
<dc:creator>Aashish Manglik</dc:creator>
<dc:date>2025-01-03</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Molecular basis of proton sensing by G protein-coupled receptors</dc:title>
<dc:identifier>pmid:39753132</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.036</dc:identifier>
</item>
<item>
<title>Evolutionary study and structural basis of proton sensing by Mus GPR4 and Xenopus GPR4</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39753131/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250104071827&amp;v=2.18.0.post9+e462414
      <description>Animals have evolved pH-sensing membrane receptors, such as G-protein-coupled receptor 4 (GPR4), to monitor pH changes related to their physiology and generate adaptive reactions. However, the evolutionary trajectory and structural mechanism of proton sensing by GPR4 remain unresolved. Here, we observed a positive correlation between the optimal pH of GPR4 activity and the blood pH range across different species. By solving 7-cryoelectron microscopy (cryo-EM) structures of Xenopus tropicalis...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 31:S0092-8674(24)01380-1. doi: 10.1016/j.cell.2024.12.001. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Animals have evolved pH-sensing membrane receptors, such as G-protein-coupled receptor 4 (GPR4), to monitor pH changes related to their physiology and generate adaptive reactions. However, the evolutionary trajectory and structural mechanism of proton sensing by GPR4 remain unresolved. Here, we observed a positive correlation between the optimal pH of GPR4 activity and the blood pH range across different species. By solving 7-cryoelectron microscopy (cryo-EM) structures of Xenopus tropicalis GPR4 (xtGPR4) and Mus musculus GPR4 (mmGPR4) under varying pH conditions, we identified that protonation of H<sup>ECL2-45.47</sup> and H<sup>7.36</sup> enabled polar network establishment and tighter association between the extracellular loop 2 (ECL2) and 7 transmembrane (7TM) domain, as well as a conserved propagating path, which are common mechanisms underlying protonation-induced GPR4 activation across different species. Moreover, protonation of distinct extracellular H<sup>ECL2-45.41</sup> contributed to the more acidic optimal pH range of xtGPR4. Overall, our study revealed common and distinct mechanisms of proton sensing by GPR4, from a structural, functional, and evolutionary perspective.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39753131/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">39753131</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.12.001>10.1016/j.cell.2024.12.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39753131</guid>
<pubDate>Fri, 03 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Xin Wen</dc:creator>
<dc:creator>Pan Shang</dc:creator>
<dc:creator>Haidi Chen</dc:creator>
<dc:creator>Lulu Guo</dc:creator>
<dc:creator>Naikang Rong</dc:creator>
<dc:creator>Xiaoyu Jiang</dc:creator>
<dc:creator>Xuan Li</dc:creator>
<dc:creator>Junyan Liu</dc:creator>
<dc:creator>Gongming Yang</dc:creator>
<dc:creator>Jiacheng Zhang</dc:creator>
<dc:creator>Kongkai Zhu</dc:creator>
<dc:creator>Qingbiao Meng</dc:creator>
<dc:creator>Xuefei He</dc:creator>
<dc:creator>Zhihai Wang</dc:creator>
<dc:creator>Zili Liu</dc:creator>
<dc:creator>Haoran Cheng</dc:creator>
<dc:creator>Yilin Zheng</dc:creator>
<dc:creator>Bifei Zhang</dc:creator>
<dc:creator>Jiaojiao Pang</dc:creator>
<dc:creator>Zhaoqian Liu</dc:creator>
<dc:creator>Peng Xiao</dc:creator>
<dc:creator>Yuguo Chen</dc:creator>
<dc:creator>Lunxu Liu</dc:creator>
<dc:creator>Fengming Luo</dc:creator>
<dc:creator>Xiao Yu</dc:creator>
<dc:creator>Fan Yi</dc:creator>
<dc:creator>Pengju Zhang</dc:creator>
<dc:creator>Fan Yang</dc:creator>
<dc:creator>Cheng Deng</dc:creator>
<dc:creator>Jin-Peng Sun</dc:creator>
<dc:date>2025-01-03</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Evolutionary study and structural basis of proton sensing by Mus GPR4 and Xenopus GPR4</dc:title>
<dc:identifier>pmid:39753131</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.12.001</dc:identifier>
</item>
<item>
<title>Correction to: Obesity and cardiovascular disease: an ESC clinical consensus statement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39749997/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250104071827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 3:ehae915. doi: 10.1093/eurheartj/ehae915. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39749997/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">39749997</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae915>10.1093/eurheartj/ehae915</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39749997</guid>
<pubDate>Fri, 03 Jan 2025 06:00:00 -0500</pubDate>
<dc:date>2025-01-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Obesity and cardiovascular disease: an ESC clinical consensus statement</dc:title>
<dc:identifier>pmid:39749997</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae915</dc:identifier>
</item>
<item>
<title>Atrial fibrillation ablation timing: where is the sweet spot?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39749989/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250104071827&amp;v=2.18.0.post9+e462414
      <description>Convincing evidence for the efficacy of ablation as first-line therapy in paroxysmal AF (PAF) and its clear superiority to medical therapy for rhythm control in both PAF and persistent AF (PsAF) has generated considerable interest in the optimal timing of ablation. Based on this data, there is a widespread view that the principle of 'the earlier the better' should be generally applied. However, the natural history of AF is highly variable and non-linear, and for this reason, it is difficult to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 3:ehae892. doi: 10.1093/eurheartj/ehae892. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Convincing evidence for the efficacy of ablation as first-line therapy in paroxysmal AF (PAF) and its clear superiority to medical therapy for rhythm control in both PAF and persistent AF (PsAF) has generated considerable interest in the optimal timing of ablation. Based on this data, there is a widespread view that the principle of 'the earlier the better' should be generally applied. However, the natural history of AF is highly variable and non-linear, and for this reason, it is difficult to be emphatic that all patients are best served by ablation early after their initial AF episodes. Sufficient evidence exists to indicate a conservative approach is reasonable in patients with infrequent and non-progressive episodes (i.e. absence of progressive increase in burden culminating in PsAF) in whom symptoms remain mild and well-controlled. A conservative management phase should be marked by assiduous attention to risk factor modification, changes in frequency and duration of AF episodes, and patient preferences. If and when AF does begin to progress, accumulating evidence indicates that early ablation accompanied by ongoing attention to risk factors provides the best outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39749989/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">39749989</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae892>10.1093/eurheartj/ehae892</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39749989</guid>
<pubDate>Fri, 03 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Jonathan M Kalman</dc:creator>
<dc:creator>Peter M Kistler</dc:creator>
<dc:creator>Gerhard Hindricks</dc:creator>
<dc:creator>Prashanthan Sanders</dc:creator>
<dc:date>2025-01-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atrial fibrillation ablation timing: where is the sweet spot?</dc:title>
<dc:identifier>pmid:39749989</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae892</dc:identifier>
</item>
<item>
<title>24-hour ambulatory blood pressure monitoring: a game changer in the management of reflex syncope?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39749974/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250104071827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 3:ehae872. doi: 10.1093/eurheartj/ehae872. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39749974/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">39749974</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae872>10.1093/eurheartj/ehae872</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39749974</guid>
<pubDate>Fri, 03 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Peter Mitro</dc:creator>
<dc:date>2025-01-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>24-hour ambulatory blood pressure monitoring: a game changer in the management of reflex syncope?</dc:title>
<dc:identifier>pmid:39749974</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae872</dc:identifier>
</item>
<item>
<title>Challenges with oral anticoagulants: bridging before surgery and concomitant use of non-steroidal anti-inflammatory drugs. Focus on revascularization of ischaemic cardiomyopathy and e-cigarettes after percutaneous coronary intervention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39749540/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250104071827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 3;46(1):1-5. doi: 10.1093/eurheartj/ehae861.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39749540/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">39749540</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae861>10.1093/eurheartj/ehae861</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39749540</guid>
<pubDate>Fri, 03 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2025-01-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Challenges with oral anticoagulants: bridging before surgery and concomitant use of non-steroidal anti-inflammatory drugs. Focus on revascularization of ischaemic cardiomyopathy and e-cigarettes after percutaneous coronary intervention</dc:title>
<dc:identifier>pmid:39749540</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae861</dc:identifier>
</item>
<item>
<title>Targeting Cardiac Fibrosis With a Vaccine Against Fibroblast Activation Protein</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39745992/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250104071827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Jan 3;136(1):41-43. doi: 10.1161/CIRCRESAHA.124.325804. Epub 2025 Jan 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39745992/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">39745992</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11698487/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">PMC11698487</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325804>10.1161/CIRCRESAHA.124.325804</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39745992</guid>
<pubDate>Thu, 02 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>William M Oldham</dc:creator>
<dc:date>2025-01-02</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Targeting Cardiac Fibrosis With a Vaccine Against Fibroblast Activation Protein</dc:title>
<dc:identifier>pmid:39745992</dc:identifier>
<dc:identifier>pmc:PMC11698487</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325804</dc:identifier>
</item>
<item>
<title>Stick to the Script: How Endomucin Keeps the Glycocalyx in Line</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39745991/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250104071827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Jan 3;136(1):75-77. doi: 10.1161/CIRCRESAHA.124.325805. Epub 2025 Jan 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39745991/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">39745991</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11698490/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">PMC11698490</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325805>10.1161/CIRCRESAHA.124.325805</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39745991</guid>
<pubDate>Thu, 02 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Ronald McMillan</dc:creator>
<dc:creator>Benjamin Rodriguez</dc:creator>
<dc:creator>Annet Kirabo</dc:creator>
<dc:date>2025-01-02</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Stick to the Script: How Endomucin Keeps the Glycocalyx in Line</dc:title>
<dc:identifier>pmid:39745991</dc:identifier>
<dc:identifier>pmc:PMC11698490</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325805</dc:identifier>
</item>
<item>
<title>Vascular-Adipose Crosstalk: Angiogenesis and Adipose Tissue Remodeling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39745990/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250104071827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Jan 3;136(1):112-114. doi: 10.1161/CIRCRESAHA.124.325899. Epub 2025 Jan 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39745990/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">39745990</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11698489/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">PMC11698489</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325899>10.1161/CIRCRESAHA.124.325899</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39745990</guid>
<pubDate>Thu, 02 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Timothy P Fitzgibbons</dc:creator>
<dc:creator>Sophia Kogan</dc:creator>
<dc:creator>Khanh-Van Tran</dc:creator>
<dc:date>2025-01-02</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Vascular-Adipose Crosstalk: Angiogenesis and Adipose Tissue Remodeling</dc:title>
<dc:identifier>pmid:39745990</dc:identifier>
<dc:identifier>pmc:PMC11698489</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325899</dc:identifier>
</item>
<item>
<title>Discovery of Titin and Its Role in Heart Function and Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39745989/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250104071827&amp;v=2.18.0.post9+e462414
      <description>This review examines the giant elastic protein titin and its critical roles in heart function, both in health and disease, as discovered since its identification nearly 50 years ago. Encoded by the TTN (titin gene), titin has emerged as a major disease locus for cardiac disorders. Functionally, titin acts as a third myofilament type, connecting sarcomeric Z-disks and M-bands, and regulating myocardial passive stiffness and stretch sensing. Its I-band segment, which includes the N2B element and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Jan 3;136(1):135-157. doi: 10.1161/CIRCRESAHA.124.323051. Epub 2025 Jan 2.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This review examines the giant elastic protein titin and its critical roles in heart function, both in health and disease, as discovered since its identification nearly 50 years ago. Encoded by the TTN (titin gene), titin has emerged as a major disease locus for cardiac disorders. Functionally, titin acts as a third myofilament type, connecting sarcomeric Z-disks and M-bands, and regulating myocardial passive stiffness and stretch sensing. Its I-band segment, which includes the N2B element and the PEVK (proline, glutamate, valine, and lysine-rich regions), serves as a viscoelastic spring, adjusting sarcomere length and force in response to cardiac stretch. The review details how alternative splicing of titin pre-mRNA produces different isoforms that greatly impact passive tension and cardiac function, under physiological and pathological conditions. Key posttranslational modifications, especially phosphorylation, play crucial roles in adjusting titin's stiffness, allowing for rapid adaptation to changing hemodynamic demands. Abnormal titin modifications and dysregulation of isoforms are linked to cardiac diseases such as heart failure with preserved ejection fraction, where increased stiffness impairs diastolic function. In addition, the review discusses the importance of the A-band region of titin in setting thick filament length and enhancing Ca²<sup>+</sup> sensitivity, contributing to the Frank-Starling Mechanism of the heart. TTN truncating variants are frequently associated with dilated cardiomyopathy, and the review outlines potential disease mechanisms, including haploinsufficiency, sarcomere disarray, and altered thick filament regulation. Variants in TTN have also been linked to conditions such as peripartum cardiomyopathy and chemotherapy-induced cardiomyopathy. Therapeutic avenues are explored, including targeting splicing factors such as RBM20 (RNA binding motif protein 20) to adjust isoform ratios or using engineered heart tissues to study disease mechanisms. Advances in genetic engineering, including CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), offer promise for modifying TTN to treat titin-related cardiomyopathies. This comprehensive review highlights titin's structural, mechanical, and signaling roles in heart function and the impact of TTN mutations on cardiac diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39745989/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">39745989</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.323051>10.1161/CIRCRESAHA.124.323051</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39745989</guid>
<pubDate>Thu, 02 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Henk L Granzier</dc:creator>
<dc:creator>Siegfried Labeit</dc:creator>
<dc:date>2025-01-02</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Discovery of Titin and Its Role in Heart Function and Disease</dc:title>
<dc:identifier>pmid:39745989</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.323051</dc:identifier>
</item>
<item>
<title>Editors and Editorial Board</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39745988/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250104071827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Jan 3;136(1):1. doi: 10.1161/RES.0000000000000706. Epub 2025 Jan 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39745988/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">39745988</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000706>10.1161/RES.0000000000000706</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39745988</guid>
<pubDate>Thu, 02 Jan 2025 06:00:00 -0500</pubDate>
<dc:date>2025-01-02</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Editors and Editorial Board</dc:title>
<dc:identifier>pmid:39745988</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000706</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39745987/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250104071827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Jan 3;136(1):2-3. doi: 10.1161/RES.0000000000000705. Epub 2025 Jan 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39745987/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">39745987</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000705>10.1161/RES.0000000000000705</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39745987</guid>
<pubDate>Thu, 02 Jan 2025 06:00:00 -0500</pubDate>
<dc:date>2025-01-02</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:39745987</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000705</dc:identifier>
</item>
<item>
<title>Cellular and Molecular Mechanisms Leading to Air Travel-Induced Thrombosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39745986/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250104071827&amp;v=2.18.0.post9+e462414
      <description>Venous thromboembolism, characterized by deep vein thrombosis and pulmonary embolism, is the third cardiovascular disease in the world. Deep vein thrombosis occurs when a blood clot forms in areas of impaired blood flow, and it is significantly affected by environmental factors. Local hypoxia, caused by venous stasis, plays a critical role in deep vein thrombosis under normal conditions, and this effect is intensified when the Po(2) decreases, such as during air travel or high-altitude exposure....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Jan 3;136(1):115-134. doi: 10.1161/CIRCRESAHA.124.325208. Epub 2025 Jan 2.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Venous thromboembolism, characterized by deep vein thrombosis and pulmonary embolism, is the third cardiovascular disease in the world. Deep vein thrombosis occurs when a blood clot forms in areas of impaired blood flow, and it is significantly affected by environmental factors. Local hypoxia, caused by venous stasis, plays a critical role in deep vein thrombosis under normal conditions, and this effect is intensified when the Po<sub>2</sub> decreases, such as during air travel or high-altitude exposure. The lower oxygen levels and reduced pressure at high altitudes further contribute to deep vein thrombosis development. These conditions increase the pro-coagulant activity of neutrophils, platelets, and red blood cells, which interact on the surface of activated endothelial cells, promoting clot formation. Understanding the mechanisms involved in thrombus formation when Po<sub>2</sub> is reduced, with or without pressure reduction, is crucial for preventing the development of venous thromboembolisms in such conditions and identifying innovative therapeutic targets. This literature review explores the mechanisms involved in thrombus formation related to high-altitude conditions and discusses the pro-coagulant consequences induced by environmental disturbances.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39745986/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">39745986</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325208>10.1161/CIRCRESAHA.124.325208</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39745986</guid>
<pubDate>Thu, 02 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Julie Tourn</dc:creator>
<dc:creator>Lydie Crescence</dc:creator>
<dc:creator>Laurie Bruzzese</dc:creator>
<dc:creator>Laurence Panicot-Dubois</dc:creator>
<dc:creator>Christophe Dubois</dc:creator>
<dc:date>2025-01-02</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Cellular and Molecular Mechanisms Leading to Air Travel-Induced Thrombosis</dc:title>
<dc:identifier>pmid:39745986</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325208</dc:identifier>
</item>
<item>
<title>Heterogeneity of Apolipoprotein B Levels Among Hispanic or Latino Individuals Residing in the US</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39745752/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250104071827&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this cohort study among participants from the HCHS/SOL, elevated apoB was present in one-quarter of a diverse cohort study of Hispanic or Latino individuals who were at intermediate or high predicted ASCVD risk. Differences in apoB distribution among Hispanic or Latino individuals may have important implications for apoB's use in ASCVD risk assessment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 2. doi: 10.1001/jamacardio.2024.4789. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Apolipoprotein B (apoB) distribution and its implications as an atherosclerotic cardiovascular disease (ASCVD) risk-enhancing factor among individuals of diverse Hispanic or Latino backgrounds have not been described.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To describe the distribution of apoB in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) cohort and to characterize associations of baseline sociodemographic and clinical variables with apoB and self-identified Hispanic or Latino background.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The HCHS/SOL was a prospective, population-based cohort study of diverse Hispanic or Latino adults living in the US who were recruited and screened between March 2008 and June 2011. Sampling weights were used to generate a population-based sample of Hispanic or Latino participants aged 18 to 74 years who resided in 4 US metropolitan areas (Bronx, New York; Chicago, Illinois; Miami, Florida; and San Diego, California). ApoB concentration was measured in participants from the HCHS/SOL, and apoB tertiles were compared across demographic groups, including self-identified Hispanic or Latino background. Median percentage continental genetic ancestry (West African, Amerindian, and European) was compared across apoB tertiles.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: ApoB measured in mg/dL from serum or plasma using an immunoturbidimetric assay.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: ApoB tertiles were determined, and traditional lipids were evaluated across apoB tertiles. ApoB and traditional lipid measurements were assessed across ASCVD risk categories. Additionally, scatterplots were created to observe correlations between apoB and low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall mean (SD) apoB concentration was 99.8 (0.4) mg/dL, with male participants displaying significantly higher mean levels than female participants (102.4 vs 97.4 mg/dL, respectively). Mean (SD) participant age was 41.1 (0.8) years, and 8376 participants (51.9%) were female. ApoB levels were higher among older age groups. There was significant heterogeneity in mean apoB concentrations across self-identified Hispanic or Latino background groups, ranging from 95.1 mg/dL in Dominican individuals to 104.8 mg/dL in Cuban individuals. The prevalence of elevated apoB (≥130 mg/dL) was greater across higher predicted ASCVD risk categories. Among participants with a 10-year predicted ASCVD risk of 7.5% or higher, 26.5% had an elevated apoB. Median West African ancestry was lower across higher tertiles of apoB.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this cohort study among participants from the HCHS/SOL, elevated apoB was present in one-quarter of a diverse cohort study of Hispanic or Latino individuals who were at intermediate or high predicted ASCVD risk. Differences in apoB distribution among Hispanic or Latino individuals may have important implications for apoB's use in ASCVD risk assessment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39745752/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">39745752</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4789>10.1001/jamacardio.2024.4789</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39745752</guid>
<pubDate>Thu, 02 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Leandro Slipczuk</dc:creator>
<dc:creator>Toshiki Kuno</dc:creator>
<dc:creator>Santica Marcovina</dc:creator>
<dc:creator>Katrina Swett</dc:creator>
<dc:creator>Kate K Orroth</dc:creator>
<dc:creator>J Antonio G López</dc:creator>
<dc:creator>Shia T Kent</dc:creator>
<dc:creator>John N Booth</dc:creator>
<dc:creator>Robert Kaplan</dc:creator>
<dc:creator>Daniela Sotres-Alvarez</dc:creator>
<dc:creator>Bharat Thyagarajan</dc:creator>
<dc:creator>Tamar Sofer</dc:creator>
<dc:creator>Martha L Daviglus</dc:creator>
<dc:creator>Gregory A Talavera</dc:creator>
<dc:creator>Parag H Joshi</dc:creator>
<dc:creator>Carlos J Rodriguez</dc:creator>
<dc:date>2025-01-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Heterogeneity of Apolipoprotein B Levels Among Hispanic or Latino Individuals Residing in the US</dc:title>
<dc:identifier>pmid:39745752</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4789</dc:identifier>
</item>
<item>
<title>Sex Differences in the Effectiveness and Safety of Aspirin</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39745729/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250104071827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 2. doi: 10.1001/jamacardio.2024.4806. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39745729/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">39745729</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4806>10.1001/jamacardio.2024.4806</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39745729</guid>
<pubDate>Thu, 02 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Marko Lucijanic</dc:creator>
<dc:creator>Eugen Javor</dc:creator>
<dc:creator>Marko Skelin</dc:creator>
<dc:date>2025-01-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Sex Differences in the Effectiveness and Safety of Aspirin</dc:title>
<dc:identifier>pmid:39745729</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4806</dc:identifier>
</item>
<item>
<title>Artificial Intelligence-Enhanced Electrocardiography for Prediction of Incident Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39745684/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250104071827&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results suggest that AIRE-HTN, an AI-ECG model, can predict incident hypertension and identify patients at risk of hypertension-related adverse events, beyond conventional clinical risk factors.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 2. doi: 10.1001/jamacardio.2024.4796. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Hypertension underpins significant global morbidity and mortality. Early lifestyle intervention and treatment are effective in reducing adverse outcomes. Artificial intelligence-enhanced electrocardiography (AI-ECG) has been shown to identify a broad spectrum of subclinical disease and may be useful for predicting incident hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To develop an AI-ECG risk estimator (AIRE) to predict incident hypertension (AIRE-HTN) and stratify risk for hypertension-associated adverse outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a development and external validation prognostic cohort study conducted at Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts, a secondary care setting. External validation was conducted in the UK Biobank (UKB), a UK-based volunteer cohort. AIRE-HTN was trained and tested to predict incident hypertension using routinely collected ECGs from patients at BIDMC between 2014 and 2023. The algorithm was then evaluated to risk stratify patients for hypertension- associated adverse outcomes and externally validated on UKB data between 2014 and 2022 for both incident hypertension and risk stratification.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: AIRE-HTN, which uses a residual convolutional neural network architecture with a discrete-time survival loss function, was trained to predict incident hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: AIRE-HTN was trained on 1 163 401 ECGs from 189 539 patients (mean [SD] age, 57.7 [18.7] years; 98 747 female [52.1%]) at BIDMC. A total of 19 423 BIDMC patients composed the test set and were evaluated for incident hypertension. From the UKB, AIRE-HTN was tested on 65 610 ECGs from same number of participants (mean [SD] age, 65.4 [7.9] years; 33 785 female [51.5%]). A total of 35 806 UKB patients were evaluated for incident hypertension. AIRE-HTN predicted incident hypertension (BIDMC: n = 6446 [33%] events; C index, 0.70; 95% CI, 0.69-0.71; UKB: n = 1532 [4%] events; C index, 0.70; 95% CI, 0.69-0.71). Performance was maintained in individuals without left ventricular hypertrophy and those with normal ECGs (C indices, 0.67-0.72). AIRE-HTN was significantly additive to existing clinical risk factors in predicting incident hypertension (continuous net reclassification index, BIDMC: 0.44; 95% CI, 0.33-0.53; UKB: 0.32; 95% CI, 0.23-0.37). In adjusted Cox models, AIRE-HTN score was an independent predictor of cardiovascular death (hazard ratio [HR] per standard deviation, 2.24; 95% CI, 1.67-3.00) and stratified risk for heart failure (HR, 2.60; 95% CI, 2.22-3.04), myocardial infarction (HR, 3.13; 95% CI, 2.55-3.83), ischemic stroke (HR, 1.23; 95% CI, 1.11-1.37), and chronic kidney disease (HR, 1.89; 95% CI, 1.68-2.12), beyond traditional risk factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results suggest that AIRE-HTN, an AI-ECG model, can predict incident hypertension and identify patients at risk of hypertension-related adverse events, beyond conventional clinical risk factors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39745684/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">39745684</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4796>10.1001/jamacardio.2024.4796</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39745684</guid>
<pubDate>Thu, 02 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Arunashis Sau</dc:creator>
<dc:creator>Joseph Barker</dc:creator>
<dc:creator>Libor Pastika</dc:creator>
<dc:creator>Ewa Sieliwonczyk</dc:creator>
<dc:creator>Konstantinos Patlatzoglou</dc:creator>
<dc:creator>Kathryn A McGurk</dc:creator>
<dc:creator>Nicholas S Peters</dc:creator>
<dc:creator>Declan P O'Regan</dc:creator>
<dc:creator>James S Ware</dc:creator>
<dc:creator>Daniel B Kramer</dc:creator>
<dc:creator>Jonathan W Waks</dc:creator>
<dc:creator>Fu Siong Ng</dc:creator>
<dc:date>2025-01-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Artificial Intelligence-Enhanced Electrocardiography for Prediction of Incident Hypertension</dc:title>
<dc:identifier>pmid:39745684</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4796</dc:identifier>
</item>
<item>
<title>Sex Differences in the Effectiveness and Safety of Aspirin-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39745683/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250104071827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 2. doi: 10.1001/jamacardio.2024.4809. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39745683/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">39745683</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4809>10.1001/jamacardio.2024.4809</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39745683</guid>
<pubDate>Thu, 02 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Catherine P Benziger</dc:creator>
<dc:creator>W Schuyler Jones</dc:creator>
<dc:date>2025-01-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Sex Differences in the Effectiveness and Safety of Aspirin-Reply</dc:title>
<dc:identifier>pmid:39745683</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4809</dc:identifier>
</item>
<item>
<title>Navigating the 2024 ESC Hypertension Guidelines: What Is New, Context, and Future Directions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39745405/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250104071827&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 30:S0735-1097(24)10475-5. doi: 10.1016/j.jacc.2024.10.114. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39745405/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">39745405</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.114>10.1016/j.jacc.2024.10.114</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39745405</guid>
<pubDate>Thu, 02 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Yuan Lu</dc:creator>
<dc:creator>Erica S Spatz</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2025-01-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Navigating the 2024 ESC Hypertension Guidelines: What Is New, Context, and Future Directions</dc:title>
<dc:identifier>pmid:39745405</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.114</dc:identifier>
</item>
<item>
<title>Systolic Blood Pressure and Pulse Pressure in Heart Failure: Pooled Participant-Level Analysis of 4 Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39745404/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250104071827&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our analysis of a large pooled dataset from 4 clinical trials, including >;16,900 patients with HFmrEF/HFpEF, indicates a J-shaped relationship between both SBP and PP and cardiovascular risk. The lowest risk was observed at SBP levels between 120 and 130 mm Hg and PP values between 50 and 60 mm Hg (I-PRESERVE [Irbesartan in Heart Failure With Preserved Systolic Function], NCT00095238; TOPCAT [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist],...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 15:S0735-1097(24)10420-2. doi: 10.1016/j.jacc.2024.11.007. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Hypertension is common in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), and current guidelines recommend treating systolic blood pressure (SBP) to a target &lt;130 mm Hg. However, data supporting treatment to this target are limited. Additionally, pulse pressure (PP), a marker of aortic stiffness, has been associated with increased risk of cardiovascular events, but its prognostic impact in HFpEF has not been extensively studied.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to explore the impact of baseline SBP and PP on cardiovascular outcomes in patients with HFmrEF or HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The I-PRESERVE (Irbesartan in Heart Failure With Preserved Ejection Fraction), TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist)-Americas, PARAGON-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With Angiotensin-Receptor Blocker Global Outcomes in HF With Preserved Ejection Fraction), and DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure) trials were global, randomized clinical trials testing irbesartan, spironolactone, sacubitril/valsartan, and dapagliflozin, respectively, against either a placebo or an active comparator (valsartan, in PARAGON-HF), in patients with heart failure and a left ventricular ejection fraction ≥40% (in DELIVER) or ≥45% (in the other trials). The relationship between continuous baseline SBP and PP, and the primary endpoint (first heart failure hospitalization or cardiovascular death) was analyzed with restricted cubic splines. We further evaluated the prognostic impact of SBP categories (&lt;120, 120-129, 130-139, and ≥140 mm Hg) and PP quartiles on the primary endpoint.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 16,950 patients (mean age 71 ± 9 years; 49% male; mean SBP 131 ± 15 mm Hg; mean PP 55 ± 14 mm Hg) were included. The relationship between SBP and the primary endpoint was J-shaped, with the lowest risk at 120 to 130 mm Hg. A similar pattern was found for PP, with the lowest risk at 50 to 60 mm Hg. The highest SBP category (reference: 120-129 mm Hg) and PP quartile (reference: 46-54 mm Hg) were associated with a higher risk of the primary outcome (HR: 1.22; 95% CI: 1.10-1.34 and HR: 1.22; 95% CI: 1.11-1.34, respectively). Higher PP was associated with greater cardiovascular risk, regardless of SBP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our analysis of a large pooled dataset from 4 clinical trials, including >;16,900 patients with HFmrEF/HFpEF, indicates a J-shaped relationship between both SBP and PP and cardiovascular risk. The lowest risk was observed at SBP levels between 120 and 130 mm Hg and PP values between 50 and 60 mm Hg (I-PRESERVE [Irbesartan in Heart Failure With Preserved Systolic Function], NCT00095238; TOPCAT [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist], NCT00094302; PARAGON-HF [Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction], NCT01920711; DELIVER [Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure], NCT03619213).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39745404/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">39745404</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.007>10.1016/j.jacc.2024.11.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39745404</guid>
<pubDate>Thu, 02 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Henri Lu</dc:creator>
<dc:creator>Toru Kondo</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brendon L Neuen</dc:creator>
<dc:creator>Iris E Beldhuis</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Finnian R Mc Causland</dc:creator>
<dc:creator>Inder S Anand</dc:creator>
<dc:creator>Marc A Pfeffer</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Michael R Zile</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:date>2025-01-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Systolic Blood Pressure and Pulse Pressure in Heart Failure: Pooled Participant-Level Analysis of 4 Trials</dc:title>
<dc:identifier>pmid:39745404</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.007</dc:identifier>
</item>
<item>
<title>The spleen in ischaemic heart disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39743566/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250104071827&amp;v=2.18.0.post9+e462414
      <description>Ischaemic heart disease is a consequence of coronary atherosclerosis, and atherosclerosis is a systemic inflammatory disease. The spleen releases various immune cells in temporally distinct patterns. Neutrophils, monocytes, macrophages, B cells and T cells execute innate and adaptive immune processes in the coronary atherosclerotic plaque and in the ischaemic myocardium. Prolonged inflammation contributes to ischaemic heart failure. The spleen is also a target of neuromodulation through vagal,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Jan 2. doi: 10.1038/s41569-024-01114-x. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ischaemic heart disease is a consequence of coronary atherosclerosis, and atherosclerosis is a systemic inflammatory disease. The spleen releases various immune cells in temporally distinct patterns. Neutrophils, monocytes, macrophages, B cells and T cells execute innate and adaptive immune processes in the coronary atherosclerotic plaque and in the ischaemic myocardium. Prolonged inflammation contributes to ischaemic heart failure. The spleen is also a target of neuromodulation through vagal, sympathetic and sensory nerve activation. Efferent vagal activation and subsequent activation of the noradrenergic splenic nerve activate β<sub>2</sub>-adrenergic receptors on splenic T cells, which release acetylcholine that ultimately results in attenuation of cytokine secretion from splenic macrophages. Coeliac vagal nerve activation increases splenic sympathetic nerve activity and drives the release of T cells, a process that depends on placental growth factor. Activation of the vagosplenic axis protects acutely from ischaemia-reperfusion injury during auricular tragus vagal stimulation and remote ischaemic conditioning. Splenectomy abrogates all these deleterious and beneficial actions on the cardiovascular system. The aggregate effect of splenectomy in humans is a long-term increase in mortality from ischaemic heart disease. The spleen has been appreciated as an important immune organ for inflammatory processes in atherosclerosis, myocardial infarction and heart failure, whereas its complex interaction with circulating blood factors and with the autonomic and somatic nervous systems, as well as its role in cardioprotection, have emerged only in the past decade. In this Review, we describe this newly identified cardioprotective function of the spleen and highlight the potential for translating the findings to patients with ischaemic heart disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39743566/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">39743566</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01114-x>10.1038/s41569-024-01114-x</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39743566</guid>
<pubDate>Wed, 01 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Gerd Heusch</dc:creator>
<dc:creator>Petra Kleinbongard</dc:creator>
<dc:date>2025-01-01</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>The spleen in ischaemic heart disease</dc:title>
<dc:identifier>pmid:39743566</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01114-x</dc:identifier>
</item>
<item>
<title>Apolipoprotein B-containing lipoproteins in atherogenesis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39743565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250104071827&amp;v=2.18.0.post9+e462414
      <description>Apolipoprotein B (apoB) is the main structural protein of LDLs, triglyceride-rich lipoproteins and lipoprotein(a), and is crucial for their formation, metabolism and atherogenic properties. In this Review, we present insights into the role of apoB-containing lipoproteins in atherogenesis, with an emphasis on the mechanisms leading to plaque initiation and growth. LDL, the most abundant cholesterol-rich lipoprotein in plasma, is causally linked to atherosclerosis. LDL enters the artery wall by...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Jan 2. doi: 10.1038/s41569-024-01111-0. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Apolipoprotein B (apoB) is the main structural protein of LDLs, triglyceride-rich lipoproteins and lipoprotein(a), and is crucial for their formation, metabolism and atherogenic properties. In this Review, we present insights into the role of apoB-containing lipoproteins in atherogenesis, with an emphasis on the mechanisms leading to plaque initiation and growth. LDL, the most abundant cholesterol-rich lipoprotein in plasma, is causally linked to atherosclerosis. LDL enters the artery wall by transcytosis and, in vulnerable regions, is retained in the subendothelial space by binding to proteoglycans via specific sites on apoB. A maladaptive response ensues. This response involves modification of LDL particles, which promotes LDL retention and the release of bioactive lipid products that trigger inflammatory responses in vascular cells, as well as adaptive immune responses. Resident and recruited macrophages take up modified LDL, leading to foam cell formation and ultimately cell death due to inadequate cellular lipid handling. Accumulation of dead cells and cholesterol crystallization are hallmarks of the necrotic core of atherosclerotic plaques. Other apoB-containing lipoproteins, although less abundant, have substantially greater atherogenicity per particle than LDL. These lipoproteins probably contribute to atherogenesis in a similar way to LDL but might also induce additional pathogenic mechanisms. Several targets for intervention to reduce the rate of atherosclerotic lesion initiation and progression have now been identified, including lowering plasma lipoprotein levels and modulating the maladaptive responses in the artery wall.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39743565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250104071827&v=2.18.0.post9+e462414">39743565</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01111-0>10.1038/s41569-024-01111-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39743565</guid>
<pubDate>Wed, 01 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Jan Borén</dc:creator>
<dc:creator>Chris J Packard</dc:creator>
<dc:creator>Christoph J Binder</dc:creator>
<dc:date>2025-01-01</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Apolipoprotein B-containing lipoproteins in atherogenesis</dc:title>
<dc:identifier>pmid:39743565</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01111-0</dc:identifier>
</item>





























</channel>
</rss>